CoChat

Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022

Open access
Plumb, Ian D., Feldstein, Leora R., Barkley, Eric, Posner, Alexander B., Bregman, Howard S., Hagen, Melissa Briggs, Gerhart, Jacqueline L. · 2022 · MMWR. Morbidity and Mortality Weekly Report
Cited by 100

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Previous infection with SARS-CoV-2, the virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron variant compared with that against other SARS-CoV-2 variants (1-3).A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or diagnosis of COVID-19.† The analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result).After previous SARS-CoV-2 infection, estimated vaccine effectiveness (VE) against COVID-19-associated hospitalization was 47.5% (95% CI = 38.8%-54.9%)after 2 vaccine doses and 57.8% (95% CI = 32.1%-73.8%)after a booster dose during the Delta-predominant period (June 20-December 18, 2021), and 34.6% (95% CI = 25.5%-42.5%)after 2 doses and 67.6% (95% CI = 61.4%-72.8%)after a booster dose during the Omicron-predominant period (December 19, 2021-February 24, 2022).Vaccination provides protection against COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection, with the highest level of protection conferred by a booster dose.All eligible persons, including those with previous SARS-CoV-2 infection, should stay up to date with vaccination to prevent COVID-19associated hospitalization.Data were obtained from Cosmos (4), an EHR data set that includes information from more than 135 million patients and * These authors contributed equally to this report.† A test-negative design is a type of vaccine effectiveness study that compares the vaccination status of persons who seek testing in the same way (in this study, with COVID-19-like illness) and received either positive results (case-patients) or negative results (control-patients).Potential selection bias is limited by including patients who receive positive or negative test results but are otherwise similar.Vaccine effectiveness is estimated as the percentage of protection by being in a specified vaccination group compared with a referent group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7115e2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Levin-Rector A, Firestein L, McGibbon E, Reduced odds of SARS-CoV-2 reinfection after vaccination among New York City adults, June–August 2021. medrxiv [Preprint posted online December 11, 2021]. https://www.medrxiv.org/content/10.1101/2021.12.09.21267203v1 · doi:10.1101/2021.12.09.21267203
  2. Cerqueira-Silva T, Andrews JR, Boaventura VS, Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect Dis 2022. Epub April 1, 2022. 10.1016/s1473-3099(22)00140-2 · DOI
  3. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Ash N, et al. Protection and waning of natural and hybrid COVID-19 immunity. medRxiv. [Preprint posted online December 5, 2021]. https://www.medrxiv.org/content/10.1101/2021.12.04.21267114v1 · doi:10.1101/2021.12.04.21267114v1
  4. Ozasa, 2008, The effect of misclassification on evaluating the effectiveness of influenza vaccines., Vaccine, 26, 6462, 10.1016/j.vaccine.2008.06.039 · DOI

Cited by

See all 100

Metadata

Authors
Plumb, I. D., Feldstein, L. R., Barkley, E., Posner, A. B., Bregman, H. S., Hagen, M. B., & Gerhart, J. L.
Venue
MMWR. Morbidity and Mortality Weekly Report
Published
2022-04-15
Volume
71
Issue
15
Pages
549-555
ISSN
  • 0149-2195 (ISSN-L)
  • 1545-861X
OpenAlex
W4223653778
Cited by
100
References
4
FWCI
11.00
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.